Article info

Extended report
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
  1. Correspondence to Dr G R Burmester, Clinic for Rheumatology and Clinical Immunology, Charité Humboldt University, Schumannstrasse 20/21, 10117 Berlin, Germany; gerd.burmester{at}charite.de
View Full Text

Citation

Burmester GR, Mease P, Dijkmans BAC, et al
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

Publication history

  • Accepted January 2, 2009
  • First published January 15, 2009.
Online issue publication 
November 12, 2009

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.